Senate Democrats were 1 vote short of overturning the Trump administration's expansion of short-term health plans; Celltrion’s CT-P10, a biosimilar to cancer drug Rituxan, received the unanimous support of an FDA advisory panel; Centene will enter 4 new states—North Carolina, Pennsylvania, South Carolina, and Tennessee—and expand offerings in 10 markets in 2019.